Management of the National Drug Administration Through the Use of Biosimilar Medicines. Expenditures, Numbers of Reimbursed Packages and Shares of Biosimilar Products in the Infliximab Market a Year Prior to and a Year after the Introduction of the National Drug Policy 2018–2022
- 20 October 2020
- journal article
- research article
- Published by University of Warsaw in Problemy Zarzadzania
- Vol. 2/2020 (88), 121-138
- https://doi.org/10.7172/1644-9584.89.7
Abstract
Purpose: Savings resulting from the use of biosimilar medicines (biosimilars) are important to the management of national drug administration. In September 2018, the Council of Ministers adopted the National Drug Policy (NDP) for 2018-2022. One of the priorities of the document set forth by the Ministry of Health was to increase the proportional use of biosimilars. The purpose of this article is to assess the changes and the dynamics in infliximab (Remicade) expenditures and the share of biosimilars within the infliximab market before and after the announcement of the NDP. Design/methodology/approach: The analysis is based on the example of infliximab, a biological medicine widely used in dermatology, gastroenterology and rheumatology. The analysis period encompasses data for one year before the document was adopted, i.e. the period from September 2017 until August 2018 (year I) as well as one year after the document came into force, i.e. the period tram September 2018 until August 2019 (yearn). Comparative analyses were based on the statistical data of monthly expenditures and the number of packages reimbursed by the National Health Fund (NHF). Fixed base and chain dynamics indices were used in the analysis. Findings: An increase in the expenditure and the number of packages sold in year II was observed for biosimilars. Research limitations/implications: It should be stressed, however, that the article pertains to a single example - the infliximab market, and that numerous other important factors may affect the sales of biosimilars. Originality/value: The analysis may be used to help evaluate the Ministry of Health's work on biosimilars.Keywords
This publication has 11 references indexed in Scilit:
- Efficacy and Safety in the Continued Treatment With a Biosimilar Drug in Patients Receiving Infliximab: A Systematic Review in the Context of Decision-Making From a Latin-American CountryFrontiers in Pharmacology, 2019
- British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adultsGut, 2019
- Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1—Biosimilar and Originator Infliximab in the Hospital SettingBioDrugs, 2019
- Effectiveness and Safety of Reference Infliximab and Biosimilar in Crohn Disease: A French Equivalence StudyAnnals of Internal Medicine, 2018
- PF-06438179/GP1111: An Infliximab BiosimilarBioDrugs, 2018
- Talking to patients about biosimilarsFuture Oncology, 2018
- Biosimilars: Concepts and controversiesPharmacological Research, 2018
- Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworksPLOS ONE, 2017
- A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeabilityDrug Design, Development and Therapy, 2017
- Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching ProgrammeJournal of Crohn's and Colitis, 2017